Submitted by jup2017 on November 8, 2017 - 11:29am
Title | Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Shojaee, Seyedmehdi, Caeser Rebecca, Buchner Maike, Park Eugene, Swaminathan Srividya, Hurtz Christian, Geng Huimin, Chan Lai N., Klemm Lars, Hofmann Wolf-Karsten, Qiu Yi Hua, Zhang Nianxiang, Coombes Kevin R., Paietta Elisabeth, Molkentin Jeffery, H Koeffler Phillip, Willman Cheryl L., Hunger Stephen P., Melnick Ari, Kornblau Steven M., and Müschen Markus |
Journal | Cancer Cell |
Volume | 28 |
Issue | 1 |
Pagination | 114-28 |
Date Published | 2015 Jul 13 |
ISSN | 1878-3686 |
Keywords | Animals, Antineoplastic Agents, Cell Transformation, Neoplastic, DNA-Binding Proteins, Dual Specificity Phosphatase 6, Host Cell Factor C1, Humans, Intracellular Signaling Peptides and Proteins, MAP Kinase Signaling System, Membrane Proteins, Mice, Mice, Transgenic, Molecular Sequence Data, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Protein Serine-Threonine Kinases, Small Molecule Libraries, Transcription Factors |
Abstract | <p>Studying mechanisms of malignant transformation of human pre-B cells, we found that acute activation of oncogenes induced immediate cell death in the vast majority of cells. Few surviving pre-B cell clones had acquired permissiveness to oncogenic signaling by strong activation of negative feedback regulation of Erk signaling. Studying negative feedback regulation of Erk in genetic experiments at three different levels, we found that Spry2, Dusp6, and Etv5 were essential for oncogenic transformation in mouse models for pre-B acute lymphoblastic leukemia (ALL). Interestingly, a small molecule inhibitor of DUSP6 selectively induced cell death in patient-derived pre-B ALL cells and overcame conventional mechanisms of drug-resistance.</p> |
DOI | 10.1016/j.ccell.2015.05.008 |
Alternate Journal | Cancer Cell |
PubMed ID | 26073130 |
PubMed Central ID | PMC4565502 |
Grant List | P30 CA016672 / CA / NCI NIH HHS / United States 101880 / WT_ / Wellcome Trust / United Kingdom U24 CA196172 / CA / NCI NIH HHS / United States R01 CA157644 / CA / NCI NIH HHS / United States R01 CA172558 / CA / NCI NIH HHS / United States R01 CA169458 / CA / NCI NIH HHS / United States U10 CA180794 / CA / NCI NIH HHS / United States U10 CA021115 / CA / NCI NIH HHS / United States UG1 CA189859 / CA / NCI NIH HHS / United States U10 CA180820 / CA / NCI NIH HHS / United States R01 CA139032 / CA / NCI NIH HHS / United States U10 CA180827 / CA / NCI NIH HHS / United States R01 CA137060 / CA / NCI NIH HHS / United States |